open access

Vol 7, No 5 (2010)
Review paper
Published online: 2010-11-15
Get Citation

Practical aspects of the use of olanzapine in the treatment of schizophrenia and bipolar disorders

Magdalena Podogrodzka, Marek Jarema
Psychiatria 2010;7(5):180-188.

open access

Vol 7, No 5 (2010)
Prace poglądowe - nadesłane
Published online: 2010-11-15

Abstract

The aim of this publication is to analyse available data on clinical indications, safety and dosing of olanzapine. Olanzapine is an atypical antipsychotic agent which has been present in clinical practice for several years. It has a pleotrophic pharmacology and affects dopaminergic, serotonergic, muscarinic and adrenergic activities. Clinical studies and trials have proven its efficiency in treating schizophrenia causing, in contrast to classical antipsychotic drugs, few extrapyramidal side effects. Olanzapine proved also to be effective in acute maniac episodes and in the maintenance treatment of bipolar disorder. The most common and problematic side effect is weight gain and subsequent metabolic disorders.
Psychiatry 2010; 7, 5: 180-188

Abstract

The aim of this publication is to analyse available data on clinical indications, safety and dosing of olanzapine. Olanzapine is an atypical antipsychotic agent which has been present in clinical practice for several years. It has a pleotrophic pharmacology and affects dopaminergic, serotonergic, muscarinic and adrenergic activities. Clinical studies and trials have proven its efficiency in treating schizophrenia causing, in contrast to classical antipsychotic drugs, few extrapyramidal side effects. Olanzapine proved also to be effective in acute maniac episodes and in the maintenance treatment of bipolar disorder. The most common and problematic side effect is weight gain and subsequent metabolic disorders.
Psychiatry 2010; 7, 5: 180-188
Get Citation

Keywords

olanzapine; efficacy; tolerability; indications

About this article
Title

Practical aspects of the use of olanzapine in the treatment of schizophrenia and bipolar disorders

Journal

Psychiatria (Psychiatry)

Issue

Vol 7, No 5 (2010)

Article type

Review paper

Pages

180-188

Published online

2010-11-15

Bibliographic record

Psychiatria 2010;7(5):180-188.

Keywords

olanzapine
efficacy
tolerability
indications

Authors

Magdalena Podogrodzka
Marek Jarema

References (49)
  1. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005; 10(1): 79–104.
  2. Zyprexa, Eli Lilly and Co. — full prescribing information. http://pi.lilly.com/us/zyprexa-pi.pdf (27.10.2010).
  3. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed Proc. 1973; 32(2): 200–205.
  4. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: Antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG. ed. Goodman and Gilman’s the pharmacological basis of therapeutics. 10 th ed. McGraw-Hill Press, New York 2001: 485–520.
  5. Farde L, Nordstrom AL, Wiesael FA, et al. Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine. Archives of General Psychiatry. 1992; 49(7): 538–544.
  6. Suhara T, Okauchi T, Sudo Y, et al. Clozapine can induce high dopamine D(2) receptor occupancy in vivo. Psychopharmacology (Berl). 2002; 160(1): 107–112.
  7. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157(4): 514–520.
  8. Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry. 1996; 3(6): 301–325.
  9. Roth BL, Meltzer HY. The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ. ed. Psychopharmacology: the fourth generation of progress. Raven Press, New York 1995: 1215–1227.
  10. Meltzer HY. Mechanism of action of atypical antipsychotic drugs. In: Davis KL, Charney D, Coyle JT, Nemeroff C. ed. Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia 2002: 819–833.
  11. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002; 47(1): 27–38.
  12. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001; 158(3): 360–369.
  13. Rosenheck R, Perlick D, Bingham S, et al. Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003; 290(20): 2693–2702.
  14. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996; 153(3): 321–330.
  15. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997; 154(4): 457–465.
  16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin. 1987; 13(2): 261–276.
  17. Tran PV, Beasley CM, Tollefson GD, et al. Olanzapine: a promising “atypical” antipsychotic agent. aprezentowane na “Fifth International Congress on Schizophrenia Research”. Colorado Springs. Colo; 1995: 12–16.
  18. Blanchard JJ, Horan WP, Collins LM, et al. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982; 39(7): 784–788.
  19. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci. 2001; 55(4): 403–414.
  20. Boter H, Peuskens J, Libiger J, et al. EUFEST study group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009; 115(2-3): 97–103.
  21. Stroup TS, Lieberman JA, McEvoy JP, et al. CATIE Investigators, CATIE Investigators, CATIE Investigators, CATIE Investigators, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209–1223.
  22. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007; 68(2): e04.
  23. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009; 39(10): 1591–1602.
  24. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009; 14(4): 429–447.
  25. Rummel-Kluge C, Komossa K, Schwarz S, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009; 166(2): 152–163.
  26. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657): 31–41.
  27. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999; 156(5): 702–709.
  28. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch. Gen. Psychiatry. 2000; 57(9): 841–849.
  29. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002; 159(6): 1011–1017.
  30. Niufan Gu, Tohen M, Qiuqing A, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord. 2008; 105(1-3): 101–108.
  31. Perlis R, Welge J, Vornik L, et al. Atypical Antipsychotics in the Treatment of Mania. The Journal of Clinical Psychiatry. 2006; 67(04): 509–516.
  32. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163(2): 247–256.
  33. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005; 162(7): 1281–1290.
  34. Parsons B, Allison DB, Loebel A, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156(11): 1686–1696.
  35. Hennen J, Perlis RH, Sachs G, et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004; 65(12): 1679–1687.
  36. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004; 24(4): 429–436.
  37. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002; 59(11): 1021–1026.
  38. McElroy SL. Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry. 2009; 70 Suppl 3: 12–21.
  39. Ehret M, Goethe J, Lanosa M, et al. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 2010; 71(10): 1286–1292.
  40. Narula PK, Rehan HS, Unni KES, et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res. 2010; 118(1-3): 218–223.
  41. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009; 29(2): 165–169.
  42. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002; 325(7358): 243–247.
  43. Lambert BL, Chou CH, Chang KY, et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf. 2005; 14(6): 417–425.
  44. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009; 374(9690): 620–627.
  45. Fric M, Laux G. [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine]. Psychiatr Prax. 2003; 30(Suppl 2): 97–101.
  46. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996; 14(2): 111–123.
  47. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. The British Journal of Psychiatry. 1999; 174(1): 23–30.
  48. Tarsy D, Baldessarini R, Tarazi F. Effects of Newer Antipsychotics on Extrapyramidal Function. CNS Drugs. 2002; 16(1): 23–45.
  49. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances [FDA Alert 4/11/05]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ ucm053171.htm (27.10.2010).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl